Pipeline
A robust pipeline to treat the most resistant cancers and neurological diseases
Hard to treat cancers and neurodegenerative diseases demand a diverse arsenal of novel therapeutic approaches.
From monoclonal and bispecific antibodies, to antibody drug conjugates, discover what we have in development.
Late-Stage Clinical Asset in Partnership with BioNTech
CTLA-4
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
Gotistobart
(ONC-392)
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Gotistobart
(ONC-392)*
Advanced solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Gotistobart
(ONC-392)
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
*In partnership with
Fully-owned clinical assets
PD-1/VEGF
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
AI-081
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
SIGLEC10
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-841
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
ONC-841
Alzheimer’s disease
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Fully-owned pre-clinical assets
CD24
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-783
Oncology
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
ONC-784
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3